Comparative Study Between Nicorandil and Nifedipine for the Treatment of Preterm Labour

NCT ID: NCT04846621

Last Updated: 2021-04-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

230 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-01

Study Completion Date

2021-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Nicorandil (potassium channel activator) is claimed to be as effective as Nifedipine (calcium channel blocker) for tocolysis in preterm labour

aim of the study: To assess the efficacy of Nicorandil compared with Nifedipine as a tocolytic agent in delaying labour for 48 hours following their administration

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preterm labour refers to a delivery that occurs between 20 weeks and before completing 37 weeks of gestation. It may or may not be preceded by preterm labor Preterm labor (PTL) is one of the leading causes of perinatal morbidity and mortality. It is one of the major public health problems, especially with reference to mortality, disability and health care expenses

The diagnosis of preterm labor based upon clinical criteria of regular painful uterine contractions occurs between 20 weeks and before 37 weeks gestation accompanied by cervical change (dilation and/or effacement). Vaginal bleeding and/or ruptured membranes in this setting increase diagnostic certainty , using the following specific criteria:

Uterine contractions (≥4 every 20 minutes or ≥8 in 60 minutes) Plus one of the following:-

* Cervical dilation equal or more than 3 cm
* Cervical length less than 20 mm on transvaginal ultrasound
* Cervical length between 20 to less than 30 mm on transvaginal ultrasound and positive fetal fibronectin test . (This criterion will not be relied upon in this study because it is costly and widely not available in most laboratories)

Since uterine contractions are the most frequently recognized sign of preterm labor, inhibition of uterine contractions with tocolytic agents to prolong pregnancy and reduce neonatal complications has been and continues to be the focus of treatment of preterm labor

• Nifedipine, a calcium channel blocker, could be used as a first line tocolytic agent

Owing to this side effects of Nifedipine, another novel drug (Nicorandil) is studied and according to literature Nicorandil is as effective as Nifedipine for tocolysis in preterm labour

is an anti-angina medication that has the dual properties of a nitrate and ATP-sensitive K+ channel activator. Nicorandil has proved to be safe as anti angina treatement in pergnency

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Labor With Preterm Delivery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants
all cases in both groups will not know which drug they receive

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group Nicorandil

women will receive oral Nicorandil 20 mg initially followed by 10 mg at 8 hourly intervals for 48 hours

Group Type OTHER

Potassium Channel Opener

Intervention Type DRUG

Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor

group Nifedipine

Women will receive oral Nifedipine loading dose 20 mg orally followed by 10 mg every 8 hours for 48 hours

Group Type OTHER

Calcium channel blocker

Intervention Type DRUG

Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Potassium Channel Opener

Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor

Intervention Type DRUG

Calcium channel blocker

Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI between (20 - 30 kg /m²).
* pregnant female with single viable fetus who presented to the outpatient clinic or Emergency room with the criteria of diagnosis of preterm labor between 28 and before completing 34 weeks pregnancy

Exclusion Criteria

* \- Any condition in which continuation of pregnancy will jeopardize maternal or fetal welfare.
* Cervix dilatation greater than 4 cm.
* Polyhydramnios \[amniotic fluid index (AFI) greater than 24 cm or deep vertical pocket more than 8 cm.\]
* Oligohydramnios (AFI less than 5 cm).
* Suspected intrauterine infection if Maternal fever is present as a constant feature plus one or more of the following:-

* Maternal leucocytosis (more than 15,000)
* purulent vaginal discharge
* Fetal tachycardia more than 180 bpm.
* Growth restriction.
* Major antepartum hemorrhage
* Major maternal medical disorders such as diabetes, hypertension, systemic lupus,liver and kidney dysfunction .
* Multiple gestation pregnancy.
* Signs of fetal non reassuring CTG
* Signs of fetal abnormal CTG
* Lethal fetal anomaly incompatible with life.
* Premature Rupture of membrane.

--Contraindication for the use of Nifedipine and/or Nicorandil such as drug allergy, cardiac disease, liver disease and kidney disease
* previous caesarean section
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Manella fayez

Miami, Alexandria Egypt

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

manella beshara, master

Role: PRINCIPAL_INVESTIGATOR

Ain Shams University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Manella Fayez Zaki Beshara

Egypt, Alexandria Governorate, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

manella beshara, master

Role: CONTACT

01271750936

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

manella beshara, master

Role: primary

01271750936

References

Explore related publications, articles, or registry entries linked to this study.

Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2.

Reference Type DERIVED
PMID: 35947046 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

preterm labor tocolysis

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nifedipine Treatment in Preterm Labor
NCT01314859 WITHDRAWN PHASE3
Vaginal Indomethacin for Preterm Labor
NCT04404686 UNKNOWN PHASE2/PHASE3
Bryophyllum vs. Nifedipine
NCT00391339 UNKNOWN PHASE2/PHASE3